Structural and Molecular Insight into Piperazine and Piperidine Derivatives as Histamine H

Analgesics / pharmacology Histamine Histamine Antagonists Histamine H3 Antagonists / pharmacology Ligands Piperazine Piperidines / pharmacology Receptors, Histamine H3 Receptors, sigma Structure-Activity Relationship Sigma-1 Receptor
dual targeting compounds dynamics functional characterization histamine H3 receptor molecular docking piperazine derivatives piperidine derivatives sigma-1 receptor sigma-2 receptor

Journal

ACS chemical neuroscience
ISSN: 1948-7193
Titre abrégé: ACS Chem Neurosci
Pays: United States
ID NLM: 101525337

Informations de publication

Date de publication:
05 01 2022
Historique:
pubmed: 16 12 2021
medline: 28 1 2022
entrez: 15 12 2021
Statut: ppublish

Résumé

In an attempt to extend recent studies showing that some clinically evaluated histamine H

Identifiants

DOI: 10.1021/acschemneuro.1c00435 PMID: 34908391 PMC: PMC8739840
pubmed: 34908391
doi: 10.1021/acschemneuro.1c00435
pmc: PMC8739840
doi:

Substances chimiques

Analgesics 0
Histamine Antagonists 0
Histamine H3 Antagonists 0
Ligands 0
Piperidines 0
Receptors, Histamine H3 0
Receptors, sigma 0
Piperazine 1RTM4PAL0V
Histamine 820484N8I3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-15

Références

Bioorg Med Chem. 2000 Aug;8(8):2105-11
pubmed: 11003156
Future Med Chem. 2014 Jun;6(10):1179-99
pubmed: 25078137
Bioorg Med Chem Lett. 2009 Mar 15;19(6):1745-8
pubmed: 19217286
Drug Discov Today. 2009 May;14(9-10):509-15
pubmed: 19429511
Physiol Behav. 2016 Oct 15;165:383-91
pubmed: 27568232
J Mol Biol. 2008 Dec 26;384(4):1002-17
pubmed: 18930735
Int J Mol Sci. 2019 Jan 23;20(3):
pubmed: 30678129
J Med Chem. 2020 May 28;63(10):5297-5311
pubmed: 32420741
Int J Mol Sci. 2020 Nov 10;21(22):
pubmed: 33182741
Neuropharmacology. 2021 Mar 15;186:108464
pubmed: 33460688
Neurology. 2010 Oct 19;75(16):1472-9
pubmed: 20956793
ACS Chem Neurosci. 2014 Mar 19;5(3):225-42
pubmed: 24422467
J Med Chem. 2018 Aug 09;61(15):6937-6943
pubmed: 29969030
Future Med Chem. 2018 Jan;10(2):231-256
pubmed: 29185346
Eur J Med Chem. 2018 Jul 15;155:492-502
pubmed: 29908442
J Med Chem. 2011 Jan 13;54(1):26-53
pubmed: 21062081
Curr Pharm Des. 2016;22(46):6935-6945
pubmed: 27669965
ChemMedChem. 2015 Jan;10(1):83-93
pubmed: 25320025
PLoS One. 2016 Aug 01;11(8):e0160003
pubmed: 27479008
Drug Discov Today. 2007 Jan;12(1-2):34-42
pubmed: 17198971
Mar Drugs. 2018 Oct 14;16(10):
pubmed: 30322188
Fundam Clin Pharmacol. 2008 Aug;22(4):387-94
pubmed: 18705749
ChemMedChem. 2010 Jul 5;5(7):1143-9
pubmed: 20512794
Eur J Med Chem. 2021 Mar 5;213:113041
pubmed: 33261900
J Med Chem. 2018 Jan 11;61(1):372-384
pubmed: 29220177
ChemMedChem. 2020 Jan 17;15(2):256-262
pubmed: 31774239
Mar Drugs. 2020 Apr 23;18(4):
pubmed: 32340389
J Pharm Pharmacol. 1958 Jan;10(1):47-59
pubmed: 13492196
ACS Med Chem Lett. 2020 Apr 09;11(5):889-894
pubmed: 32435401
ChemMedChem. 2009 Feb;4(2):225-31
pubmed: 19101971
Int J Mol Sci. 2020 Aug 14;21(16):
pubmed: 32824072
J Med Chem. 2019 Jan 24;62(2):420-444
pubmed: 30035545
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18676-81
pubmed: 20956312
J Pharmacol Sci. 2015 Jan;127(1):2-5
pubmed: 25704011
Inflamm Res. 2015 Jun;64(6):377-81
pubmed: 25902777
J Physiol Pharmacol. 2006 Jun;57(2):217-29
pubmed: 16845227
J Med Chem. 2017 Dec 14;60(23):9531-9544
pubmed: 29172528
Bioorg Med Chem. 2012 Aug 15;20(16):5033-41
pubmed: 22824762
Eur J Med Chem. 2020 Dec 1;207:112743
pubmed: 32882609
ACS Chem Biol. 2016 Feb 19;11(2):400-8
pubmed: 26569370
J Med Chem. 2007 Jul 12;50(14):3194-204
pubmed: 17579383
J Chem Inf Model. 2013 Aug 26;53(8):1893-904
pubmed: 23379370
Eur J Med Chem. 2017 Jan 5;125:603-610
pubmed: 27721146
Mar Drugs. 2019 Oct 31;17(11):
pubmed: 31683588
Brain Res. 1995 Feb 27;673(1):61-9
pubmed: 7757480
Mini Rev Med Chem. 2005 Oct;5(10):927-40
pubmed: 16250835
Pharmacol Res. 2021 Jan;163:105339
pubmed: 33276102
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Curr Med Chem. 2021;28(15):2974-2995
pubmed: 32767910
Bioorg Med Chem Lett. 2020 Nov 15;30(22):127522
pubmed: 32871268
J Mol Model. 2004 Apr;10(2):155-64
pubmed: 14997367
Front Biosci (Schol Ed). 2012 Jan 01;4:461-88
pubmed: 22202071
ACS Chem Neurosci. 2018 Mar 21;9(3):401-403
pubmed: 29465220
Neuropharmacology. 2013 Jul;70:348-58
pubmed: 23524304
Nat Rev Drug Discov. 2005 Jan;4(1):71-8
pubmed: 15688074
Sci Rep. 2020 Aug 11;10(1):13558
pubmed: 32782417
ACS Chem Neurosci. 2017 Aug 16;8(8):1801-1811
pubmed: 28644012
Drug Discov Today Technol. 2013 Dec;10(4):e483-9
pubmed: 24451638
Bioorg Med Chem. 2018 Dec 15;26(23-24):6056-6066
pubmed: 30448256
Eur J Med Chem. 2010 Jan;45(1):256-63
pubmed: 19875205
Eur J Pharmacol. 2013 Sep 15;716(1-3):78-93
pubmed: 23500210
Bioorg Chem. 2019 Sep;90:103084
pubmed: 31271942
Cell. 2007 Nov 2;131(3):596-610
pubmed: 17981125
Bioorg Chem. 2019 Oct;91:103071
pubmed: 31362197
J Med Chem. 2021 Aug 12;64(15):11695-11708
pubmed: 34309390
Neuropharmacology. 2018 Jun;135:328-342
pubmed: 29580951
J Med Chem. 2008 Feb 14;51(3):347-72
pubmed: 18181565
Eur J Med Chem. 2018 May 25;152:223-234
pubmed: 29723785
Br J Pharmacol. 2015 May;172(10):2519-31
pubmed: 25573298
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
pubmed: 4202581
J Pharmacol Exp Ther. 2014 Jan;348(1):32-45
pubmed: 24155346
J Psychiatry Neurosci. 2017 Jan;42(1):59-69
pubmed: 27636528
Neuropharmacology. 2019 Jan;144:244-255
pubmed: 30359639
Angew Chem Int Ed Engl. 2017 Oct 2;56(41):12765-12769
pubmed: 28861918
Pharmacol Ther. 2019 Aug;200:69-84
pubmed: 31028835

Auteurs

Katarzyna Szczepańska (K)

Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland.
Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, Kraków 31-343, Poland.

Sabina Podlewska (S)

Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland.
Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, Kraków 31-343, Poland.
ORCID: 0000-0002-2891-5603

Maria Dichiara (M)

Department of Drug and Health Sciences, University of Catania, V.le A. Doria, 95125 Catania, Italy.

Davide Gentile (D)

Department of Drug and Health Sciences, University of Catania, V.le A. Doria, 95125 Catania, Italy.

Vincenzo Patamia (V)

Department of Drug and Health Sciences, University of Catania, V.le A. Doria, 95125 Catania, Italy.
ORCID: 0000-0002-0048-2631

Niklas Rosier (N)

Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, Universitätsstraße 31, D-93053 Regensburg, Germany.

Denise Mönnich (D)

Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, Universitätsstraße 31, D-93053 Regensburg, Germany.

Ma Carmen Ruiz Cantero (MC)

Department of Pharmacology and Neurosciences Institute (Biomedical Research Center) and Biosanitary Research Institute ibs.GRANADA, University of Granada, Avenida de la Investigación 11, 18016 Granada, Spain.
ORCID: 0000-0001-6968-0946

Tadeusz Karcz (T)

Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland.

Dorota Łażewska (D)

Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland.

Agata Siwek (A)

Department of Pharmacobiology, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland.

Steffen Pockes (S)

Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, Universitätsstraße 31, D-93053 Regensburg, Germany.
ORCID: 0000-0002-2211-9868

Enrique J Cobos (EJ)

Department of Pharmacology and Neurosciences Institute (Biomedical Research Center) and Biosanitary Research Institute ibs.GRANADA, University of Granada, Avenida de la Investigación 11, 18016 Granada, Spain.

Agostino Marrazzo (A)

Department of Drug and Health Sciences, University of Catania, V.le A. Doria, 95125 Catania, Italy.
ORCID: 0000-0002-8728-8857

Holger Stark (H)

Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, 40225 Duesseldorf, Germany.
ORCID: 0000-0003-3336-1710

Antonio Rescifina (A)

Department of Drug and Health Sciences, University of Catania, V.le A. Doria, 95125 Catania, Italy.
ORCID: 0000-0001-5039-2151

Andrzej J Bojarski (AJ)

Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, Kraków 31-343, Poland.
ORCID: 0000-0003-1417-6333

Emanuele Amata (E)

Department of Drug and Health Sciences, University of Catania, V.le A. Doria, 95125 Catania, Italy.
ORCID: 0000-0002-4750-3479

Katarzyna Kieć-Kononowicz (K)

Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland.

Articles similaires

New emerging treatment options for metastatic melanoma: a systematic review and meta-analysis of skin cancer therapies.

Anan S Jarab, Walid A Al-Qerem, Lina M Khdour et al.
1.00
Humans Melanoma Skin Neoplasms Antineoplastic Combined Chemotherapy Protocols Randomized Controlled Trials as Topic

A head-to-head comparison of MM/PBSA and MM/GBSA in predicting binding affinities for the CB

Mei Qian Yau, Clarence W Y Liew, Jing Hen Toh et al.
1.00
Receptor, Cannabinoid, CB1 Ligands Molecular Dynamics Simulation Protein Binding Thermodynamics

Flavopiridol induces cell cycle arrest and apoptosis by interfering with CDK1 signaling pathway in human ovarian granulosa cells.

Xiao-Zhen Li, Wei Song, Zheng-Hui Zhao et al.
1.00
Humans Flavonoids Female Apoptosis Granulosa Cells

Heart rate variability analysis for the prediction of pre-arousal during propofol-remifentanil general anaesthesia: A feasibility study.

Anne Wojtanowski, Maxence Hureau, Camille Ternynck et al.
1.00
Humans Heart Rate Anesthesia, General Propofol Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Analgésiques › Structural and Molecular Insight into...
questionsmedicales.fr › Facteurs biologiques › Médiateurs de l'inflammation › Autacoïdes › Histamine › Structural and Molecular Insight into...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents histaminiques › Antihistaminiques › Structural and Molecular Insight into...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents histaminiques › Antihistaminiques › Antihistaminiques des récepteurs H3 › Structural and Molecular Insight into...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Ligands › Structural and Molecular Insight into...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipérazines › Pipérazine › Structural and Molecular Insight into...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipéridines › Structural and Molecular Insight into...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs histaminergiques › Récepteur histaminergique H3 › Structural and Molecular Insight into...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur aux neuropeptides › Récepteurs aux opioïdes › Récepteur sigma › Structural and Molecular Insight into...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › Structural and Molecular Insight into...